21 results about "Lyotropic liquid crystal" patented technology

The invention discloses an anionic surfactant and a preparation method and application thereof.The anionic surfactant has a double-wedge-shaped molecular structure, alkaline earth metal benzene sulfonate serves as a polar hydrophilic wedge tip, a long-chain alkoxy flexible chain segment serves as a hydrophobic wedge group, the surface tension of water can be remarkably reduced in an aqueous solution, and the anionic surfactant has excellent emulsifying capacity. The molecular structure is based on alkaline earth metal benzene sulfonate and has good thermotropic and lyotropic liquid crystallinity, the liquid crystal phase temperature range of the molecular structure exceeds 140 DEG C, and the phase transition temperature and the mesogenic state temperature range can be controlled by adjusting the number of carbon atoms of an alkoxy substituent. When in a mesogenic state, the molecules can form a supramolecular columnar phase through self-assembly aggregation, and the columnar structure can form a transmission channel with ion recognition in the column center direction. By utilizing the characteristic, a novel bionic ion selective conduction membrane can be constructed, and the biomimetic ion selective conduction membrane has wide application potential in the aspects of preparation of ion selective electrodes and chemical sensors and the like.

An antimicrobial amphiphilic hydrogel composition for use in haemostasis of a wound comprising: a first cross-linkable amphiphilic component, the first amphiphilic component, in its chemically cross-linked state, being a lyotropic liquid crystal and having an ordered nanostructure of hydrophobic and hydrophilic domains, the hydrogel comprising an antimicrobial agent covalently attached to the hydrophilic and / or hydrophobic domains.

Nonlinear optical chromophore compositions which display lyotropic nematic liquid crystal phases in polar organic solvents and provide a mechanical anisotropic effect allowing for the formation of a non-centrosymmetric chromophore-polymer matrix without the application of an electric field.

The present application relates to a kind of pH response type lyotropic liquid crystal drug delivery system, its preparation method and application.The system includes phospholipid component, inverse liquid crystal induced lipid, organic solvent, pH response gate switch and positively charged therapeutic active substance.The system is flowable liquid before injection, forms lyotropic liquid crystal gel in situ after entering aqueous environment;Under physiological pH condition, pH response gate switch and cationic drug occur electrostatic interaction, so that system maintains inverse hexagonal phase and limits drug release;Under acidic pathological microenvironment, gate switch is protonated and induces system to transform to double-continuous inverse cubic phase, so as to promote sustained drug release.The present application can be used for the local treatment of solid tumor, bacterial infection, chronic inflammation and wound repair and other diseases accompanied by local acidic microenvironment.

The invention relates to a preparation method of a metal-based silver nanostructure array material. According to the invention, the metal-based silver nanostructure array material is prepared by utilizing a replacement reaction between active metal atoms and silver ions and by virtue of a method for assisting self-assembly synergistic growth of the silver ions by virtue of a lyotropic liquid crystal soft template. By means of the method, the silver nanostructure array with the adjustable size and the controllable morphology can be prepared, the preparation method is simple, large instruments and equipment are not needed, the method is suitable for mass production of silver nanostructure array materials with the uniform morphology, and the prepared metal-based silver nanostructure array material can be used for the related fields of the surface enhanced spectrum technology, photocatalysis and the like.

The present application relates to the technical field of plant oil preparation, and particularly relates to a sunflower seed oil preparation method and a scar repair protein polypeptide for application. The present application discloses a sunflower seed oil preparation method, which comprises the following steps: firstly, sunflower seeds are dried, impurities are removed, the sunflower seeds are shelled and crushed to obtain sunflower seed powder; secondly, an extracting agent is used to obtain a crude extract through ultrasonic treatment, filtration and static stratification; thirdly, a lyotropic liquid crystal agent is used for decolorization to obtain a secondary extract; fourthly, under the alkaline condition of oxalyl chloride solution and triethylamine solution, a purified membrane is used to remove free fatty acids, and then the remaining impurities and solvent are removed through rotary evaporation to obtain sunflower seed oil; fifthly, the sunflower seed oil is embedded by a layered adsorbent to obtain a sunflower seed oil-magnesium aluminum-oleic acid-layered double hydroxide compound; and finally, the sunflower seed oil-magnesium aluminum-oleic acid-layered double hydroxide compound is mixed with collagen protein polypeptide to form a scar repair protein polypeptide, so that the protection, slow release, hydrophilicity and biocompatibility of the sunflower seed oil are realized.

The invention relates to a solid electrolyte with a lyotropic liquid crystal nano structure, which is obtained by realizing nano confinement of an aqueous zinc ion battery electrolyte by using commercialized amphiphilic molecules. The amphiphilic molecules adopted by the method have the advantages of low cost and good curing performance. A lyotropic liquid crystal structure is introduced into the aqueous electrolyte, so that a zinc ion efficient transmission channel can be effectively constructed, and the efficiency of the zinc ion battery is enhanced. Meanwhile, the introduction of the lyotropic liquid crystal electrolyte can effectively solve the problems of narrow electrochemical window, unstable interface, easy dendritic crystal corrosion and unstable interface of the zinc ion battery, and meanwhile, the lyotropic liquid crystal dynamic ordered structure can effectively improve the stability and infiltration effect of the solid electrolyte and the interface, so that efficient and durable operation of the zinc ion battery is realized. The lyotropic liquid crystal aqueous electrolyte has the following advantages and outstanding effects that the raw material for constructing the lyotropic liquid crystal aqueous electrolyte is commercialized amphiphilic molecules, and the lyotropic liquid crystal aqueous electrolyte has the characteristics of being convenient to operate, low in cost and high in environmental benefit. The process for constructing the lyotropic liquid crystal electrolyte is simple, convenient to operate and suitable for realizing large-scale batch industrial preparation. The obtained electrolyte has the charge transfer characteristic of a liquid electrolyte and the intrinsic stability of a solid electrolyte, the problems of narrow electrochemical window, unstable interface, easy dendritic crystal corrosion and unstable interface of the zinc ion battery can be solved, and efficient and durable operation of the zinc ion battery is realized. Therefore, the process has the characteristics of low cost, low investment and environmental protection.

This invention discloses a composition for preparing flexible composite films and its application, relating to the field of engineering plastic materials technology. The composition comprises the following raw materials by weight: 40-60 parts of lyotropic liquid crystal polymer, 20-40 parts of polytetrafluoroethylene powder, and 10-30 parts of modified Mg3B2O6 ceramic powder; the modified Mg3B2O6 ceramic powder is obtained by grinding Mg3B2O6 ceramic powder in an organic solvent with a surface modifier, followed by drying. The surface modifier is 1-3 wt% of the Mg3B2O6 ceramic powder and is selected from at least one of stearic acid and silane coupling agent KH550. This invention uses a surface modifier to modify the surface of Mg3B2O6 ceramic powder, which acts as a functional bridge between inorganic ceramic particles and LLCP / PTFE composite membrane, improves the interfacial compatibility between Mg3B2O6 ceramic powder and organic matter, promotes the uniform dispersion of Mg3B2O6 ceramic powder in organic matter, reduces the porosity of composite material, and is beneficial to reducing the thermal expansion coefficient and dielectric loss of composite membrane, thus giving the composite membrane better performance.

The application relates to the technical field of A61K8 / 00, in particular to a coconut amino acid mild facial cleanser with a solvated liquid crystal structure and a preparation process, which at least comprises the following components in percentage by mass: coconut amino acid 28-39%, a first conditioning component 10-15%, a second conditioning component 1-2%, glycerol 15-30%, a stabilizing agent 0.3-0.8%, citric acid 1.5-2.2%, a functional auxiliary agent 1.5-2%, and water to make up the balance; high-content potassium lauroyl glutamate is introduced to realize the non-tightness of moisturizing after cleaning, the better cleaning power and the clean and fresh feeling after washing, the specific process is further matched, the facial cleanser product prepared in the subsequent preparation is ensured to have a bright pearl appearance, the cream is fine and stable, and the use experience of subsequent consumers is further ensured.

The application discloses a glucose detection method based on lyotropic liquid crystal droplets, polyethyleneimine is dissolved in 0.2M NaH2PO4-Na2HPO4 buffer solution with pH value of 7.8 to obtain a polyethyleneimine aqueous solution, cromolyn sodium is added, heated and uniformly mixed to obtain a polyethyleneimine doped cromolyn sodium aqueous solution, glucose oxidase is added to a to-be-detected glucose sample to obtain a mixed solution, the mixed solution is dropped into a liquid crystal cell composed of two parallel glass plates as a test group, meanwhile, blank liquid crystal cells, liquid crystal cells only dropping the to-be-detected glucose sample and liquid crystal cells only dropping a glucose oxidase aqueous solution are used as control groups, the polyethyleneimine doped cromolyn sodium aqueous solution is heated to 60 DEG C and then is dropped into the test group and the control group liquid crystal cells preheated to 60 DEG C, and the droplet morphology is observed under a polarizing microscope. Compared with the prior art, the method is simple in operation, free from current interference, low in cost and high in sensitivity.

The invention belongs to the technical field of pharmaceutical preparations, and particularly discloses an anti-schizophrenia lyotropic liquid crystal long-acting injection and a preparation method and application thereof, and the anti-schizophrenia lyotropic liquid crystal long-acting injection is composed of an anti-schizophrenia drug, an amphiphilic compound and an organic solvent; the anti-schizophrenia medicine is selected from any one of brexpiprazole, cariprazine and aripiprazole; the amphiphilic compound is selected from any one or more of soybean phosphatidylcholine, egg yolk phosphatidylcholine, glyceryl monooleate, glyceryl monopalmitate, glyceryl dioleate, glyceryl trioleate, vitamin E acetate and phytantriol; the organic solvent is selected from one or more of ethanol, N-methyl pyrrolidone, dimethyl sulfoxide and 1, 2-propylene glycol. The anti-schizophrenia lyotropic liquid crystal in-situ gel long-acting injection forms a stable semi-solid drug reservoir through solvent exchange after administration so as to play a therapeutic effect in long-acting treatment of positive schizophrenia and negative schizophrenia and prevention of schizophrenia relapse.

The invention discloses a lyotropic liquid crystal long-acting injection as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The preparation consists of a raw material medicine, a lipid material, an organic solvent and a release regulator, and hexagonal phase liquid crystal gel can be spontaneously formed after injection so as to realize long-acting slow release. The preparation can be prepared by stirring and mixing at room temperature, and has the advantage of simple and convenient preparation process. Experiments show that the effective blood concentration in the body can be maintained for more than 14 days after single hypodermic injection, the half-life period of the medicine is prolonged to 187 hours from about 66 hours of oral administration, and the burst release phenomenon is avoided. The invention effectively solves the clinical pain points of frequent administration, large blood concentration fluctuation, poor patient compliance and the like of the existing oral preparation of the hydrobromic acid vortioxetine.

The invention discloses a rotigotine lyotropic liquid crystal precursor solution as well as a preparation method and application thereof, and belongs to the field of pharmaceutical preparations, the rotigotine lyotropic liquid crystal precursor solution comprises the following components: phospholipid, grease, a release regulator, an organic solvent and rotigotine or pharmaceutically acceptable salt thereof, the organic solvent accounts for 10-40% of the mass of the precursor, and the rotigotine or pharmaceutically acceptable salt thereof accounts for 1-30% of the mass of the precursor. The rotigotine lyotropic liquid crystal precursor solution is low in viscosity and easy to inject, lyotropic liquid crystal gel can be formed when the rotigotine lyotropic liquid crystal precursor solution encounters body fluid after injection, and the gel wraps a medicine to be slowly released, so that the rotigotine lyotropic liquid crystal precursor solution has a good slow-release effect, the medication frequency can be reduced, and the compliance of a patient is improved; the auxiliary materials are good in biocompatibility, and do not easily cause inflammatory response of the organism; the production cost is low, and the preparation method is simple and easy to industrialize. The invention can be used for auxiliary treatment of early primary Parkinson's disease and late primary Parkinson's disease.

The invention discloses a moxidectin long-acting injection and a preparation method thereof, and belongs to the technical field of biological medicines. The moxidectin long-acting injection takes moxidectin as an active component, and is combined with neutral diacyl ester, phospholipid and an organic solvent to form a low-viscosity pre-preparation. After injection, the preparation is subjected to phase change when encountering body fluid in vivo to form a lyotropic liquid crystal type gel storage cavern, so that slow release of the medicine is realized, the medicine effect is remarkably prolonged, and the administration frequency is reduced. The preparation is good in needle passing performance, high in biocompatibility, simple in preparation process and suitable for industrial production, and can be effectively used for long-term prevention and treatment of pet parasites.

The application discloses a preparation method of a chiral ferromagnetic monodomain liquid crystal material, and synthesizes Sc-doped barium ferrite nanosheets through a hydrothermal method, modifies the nanosheets by using citric acid, obtains ferromagnetic barium ferrite nanosheets, and uniformly disperses the ferromagnetic barium ferrite nanosheets into a chiral liquid crystal matrix; under the action of a weak magnetic field (as low as 30 mT), the anisotropic nanosheet orientation is coupled with the chiral liquid crystal orientation, the nanosheets are oriented along the magnetic field direction, and the ordered arrangement of the chiral liquid crystal matrix is guided; the chiral cluster aggregates and liquid crystal domains in the chiral liquid crystal matrix are migrated and fused, and finally, a wireless, planar defect chiral ferromagnetic monodomain structure is formed. The chiral ferromagnetic monodomain liquid crystal material has magnetic response, and the magneto-optic effect under the action of a magnetic field provides a basis for the application of the chiral ferromagnetic monodomain liquid crystal material in the fields of optical equipment and flexible machines.

The present invention provides compositions and methods for treating, or attenuating and / or preventing skin barrier disruptions, skin insults and skin conditions in a subject. The lyotropic liquid crystal composition of the invention comprises at least one of phase changing material, and at least one stratum corneum component.

A solid antimicrobial hydrogel comprising a first amphiphilic component. The first amphiphilic component, in its chemically cross-linked state, being a lyotropic liquid crystal and having an ordered nanostructure of hydrophobic and hydrophilic domains, the composition further comprising an antimicrobial agent being covalently attached to at least one of the hydrophilic or hydrophobic domains.

This invention belongs to the field of pharmaceutical formulation technology, specifically relating to a bortezomib lyotropic liquid crystal precursor composition, its preparation method, and its application. The bortezomib lyotropic liquid crystal precursor composition comprises bortezomib and a lyotropic liquid crystal carrier, wherein the ratio of bortezomib to the lyotropic liquid crystal carrier is 0.8-10 mg:1 mL; the lyotropic liquid crystal carrier comprises soybean phosphatidylcholine, α-tocopherol, dioleoylglycerol, and anhydrous ethanol in a mass ratio of 40-48:30-40:10:10-15. Experimental verification shows that the bortezomib lyotropic liquid crystal precursor composition provided by this invention can be converted into a structurally stable liquid crystal phase after subcutaneous injection, achieving effective encapsulation and slow release of bortezomib, thereby significantly prolonging the drug's duration of action in vivo, reducing local reactions, and exhibiting long-acting, safe, and stable characteristics.

The invention discloses a lyotropic liquid crystal nanoparticle, a nano pesticide and application of the lyotropic liquid crystal nanoparticle and the nano pesticide. Mixing glycerol monooleate, oleic acid and the polyoxyethylene polyoxypropylene ether triblock copolymer, and heating to obtain a blend; and adding a buffer solution into the blend, homogenizing, adjusting the pH value, and standing to obtain the lyotropic liquid crystal nanoparticles. The nano pesticide is obtained by taking lyotropic liquid crystal as a carrier and loading an insecticide S-fenvalerate. The lyotropic liquid crystal is prepared from glycerol monooleate, oleic acid and polyoxyethylene polyoxypropylene ether triblock copolymer through self-assembly, hydrophilic groups and hydrophobic groups are contained between layers of the lyotropic liquid crystal, and the lyotropic liquid crystal can be combined with an insecticide containing the hydrophilic groups or the hydrophobic groups, so that the nano pesticide is obtained by loading the insecticide. The prepared nano pesticide has excellent wettability and stability, and the lyotropic liquid crystal serves as a novel pesticide carrier, so that a new way is provided for research of the nano pesticide.

This invention relates to spinning solutions for aramid and carbon nanotube composite fibers and methods for preparing aramid and carbon nanotube composite fibers using the same. The spinning solution for aramid and carbon nanotube composite fibers of this invention comprises: aramid; carbon nanotubes; and a superacid exhibiting a lyotropic liquid crystal phase. This invention allows for the preparation of aramid and carbon nanotube composite fibers using a single process without additional steps for adjusting the orientation of the aramid and carbon nanotubes, and enables the preparation of aramid and carbon nanotube composite fibers with improved specific strength and specific conductivity.

Provided is a composition capable of forming an optically anisotropic film exhibiting reverse wavelength dispersibility and an Nz factor of about 0.50 (0.40 to 0.60); as well as an optically anisotropic, a circularly polarizing plate, and a display device. The composition includes a non-colorable rod-like compound having an acid group or a salt thereof, a non-colorable plate-like compound having an acid group or a salt thereof, and a salt consisting of a cation and an anion, and exhibiting lyotropic liquid crystallinity, in which a ratio W obtained by Expression (W) is 0.25 to 1.75, and a maximum absorption wavelength in a wavelength range of 230 to 400 nm of the rod-like compound is smaller than a maximum absorption wavelength in a wavelength range of 230 to 400 nm of the plate-like compound.Ratio⁢ W=(C⁢1+C⁢2+C⁢3)-(A⁢1+A⁢2)A⁢2(W)